C1 inhibitor function using contact‐phase proteases as target: evaluation of an innovative assay

E-ISSN： 1398-9995|70|9|1103-1111

ISSN： 0105-4538

Source： ALLERGY, Vol.70, Iss.9, 2015-09, pp. : 1103-1111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1817-1826

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

ALLERGY, Vol. 105-4538, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

ALLERGY, Vol. 70, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 1011-1019

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the immune function assay in pediatric living donor liver transplantation

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 2, 2015-03 ,pp. : 144-152

John Wiley & Sons Inc

Access to resources Recommend Favorite